Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01092026|
Recruitment Status : Recruiting
First Posted : March 24, 2010
Last Update Posted : June 6, 2016
A pilot study to assess the feasibility of unrelated umbilical cord blood transplantation with coinfusion of third-party mesenchymal stem cells after myeloablative or nonmyeloablative conditioning in patients with hematological malignancies.
This is a multicenter single arm, phase I-II pilot study. The primary objective of this study is to determine the feasibility of UCB HSCT with co-infusion of third party mesenchymal stem cells as assessed by the treatment-related mortality at d100 after transplant.
Patient inclusion criteria:
Age 15-60 yrs Patients for whom allogeneic stem cell transplantation is the preferred treatment option, with the following hematological malignancies:acute myeloid leukemia, acute lymphoblastic leukemia, high risk myelodysplastic syndrome, advanced lymphoproliferative disorders, chronic myeloid leukemia (refractory or intolerant to second-line tyrosine kinase inhibitors), multiple myeloma Informed consent given Patient exclusion criteria Previous allogeneic transplant Progressive malignant disease Significant organ damage as a contraindication to allotransplantation Significant psychiatric or neurological disorder Uncontrolled viral, fungal or bacterial infection Pregnancy HIV positive Patients will receive either myeloablative or reduced intensity conditioning. One or 2 cord blood transplants will be transplanted, followed by infusion of a third-party mesenchymal stem cell transplant Adverse event reporting BHS transplant committee will establish a protocol review committee which will organize a central monitoring of the study. Within the context of allogeneic HSCTx many severe events are likely to occur.
Statistics and stopping rules The trial will be stopped at any time that there is reasonable evidence that the true rate of day +100 nonrelapse mortality exceeds 0.40. It is the intention to include an initial 20 patients.
|Condition or disease||Intervention/treatment||Phase|
|Allogeneic Stem Cell Transplantation||Other: cord blood transplantation||Phase 1 Phase 2|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Study to Assess the Feasibility of Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Third-party Mesenchymal Stem Cells After Myeloablative or Nonmyeloablative Conditioning in Patients With Hematological Malignancies|
|Study Start Date :||November 2010|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2017|
Experimental: cord blood transplant
Eiligible patients receive cord blood transplantation with coinfusion of mesenchymal stem cells
Other: cord blood transplantation
One or two cord blood transplants with co-infusion of third-party mesenchymal stem cells after pre-transplant preparative regimen
- treatment-related mortality [ Time Frame: day 100 after transplant ]
- Hematopoietic recovery [ Time Frame: One year after transplant ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01092026
|Contact: Rik Schots, MD, PhD||+3224763105||Rik.Schots@uzbrussel.be|
|Contact: Dorien Deneve||+3224776040||Dorien.Deneve@uzbrussel.be|
|Brussel, Belgium, 1090|
|Contact: Rik Schots, MD, PhD +3224776211 Rik.Schots@uzbrussel.be|
|Contact: Dorien Deneve +3224776040 Dorien.Deneve@uzbrussel.be.be|
|Principal Investigator:||Rik Schots, MD, PhD||Universitair Ziekenhuis Brussel|